Abbott Laboratories
NYSE:ABT · New York Stock Exchange
-$0.51 today
Vol 10.41M · Avg 13.17M
Balance Sheet
Inspect the capital base behind the business
Review assets, liabilities, equity, cash, and debt to judge whether the company has the financial position to support future returns.
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $6.8B |
| Short-term Investments | $492.0M |
| Receivables | $8.2B |
| Inventory | $7.0B |
| Other Current | $3.0B |
| Total Current Assets | $25.5B |
| PP&E (Net) | $12.4B |
| Goodwill | $35.2B |
| Intangible Assets | $17.9B |
| Long-term Investments | $1.1B |
| Other Non-current | $18.4B |
| Total Non-current Assets | $84.9B |
| Total Assets | $110.4B |
Analysis
Selected assets total $110.4B for Latest. The largest visible component is Goodwill at $35.2B, about 31.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Balance Sheet
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.5B +11.9% | $7.6B +10.4% | $6.9B -30.2% | $9.9B +0.8% | $9.8B | $1.0B | $841.8M | $673.8M |
| Short-term Investments | $417.0M +18.8% | $351.0M -8.4% | $383.0M +33.0% | $288.0M -36.0% | $450.0M | -$1.6B | $445.6M | $378.4M |
| Net Receivables | $7.9B +14.5% | $6.9B +5.5% | $6.6B +5.6% | $6.2B -4.1% | $6.5B | $533.8M | $399.4M | -$1.7B |
| Inventory | $6.5B +4.7% | $6.2B -5.7% | $6.6B +6.4% | $6.2B +19.7% | $5.2B | $641.6M | $328.0M | $316.8M |
| Other Current Assets | $2.6B +2.7% | $2.6B +13.9% | $2.3B -15.3% | $2.7B +13.5% | $2.3B | $1.5B | $966.4M | $764.8M |
| Total Current Assets | $26.0B +9.9% | $23.7B +4.3% | $22.7B -10.1% | $25.2B +4.1% | $24.2B | $12.5B | $10.5B | $5.5B |
| Property, Plant & Equipment (Net) | $12.9B +10.3% | $11.7B +4.1% | $11.3B +9.7% | $10.3B +1.6% | $10.1B | $1.2B | $1.5B | $687.8M |
| Goodwill | $24.0B +4.0% | $23.1B -2.4% | $23.7B +3.9% | $22.8B -1.9% | $23.2B | $925.8M | $466.6M | $309.8M |
| Intangible Assets | $5.5B -16.9% | $6.6B -24.6% | $8.8B -15.7% | $10.5B -17.9% | $12.7B | $568.8M | $860.0M | $1.5B |
| Long-term Investments | $918.0M +3.6% | $886.0M +10.9% | $799.0M +4.3% | $766.0M -15.2% | $903.0M | $524.0M | -$1.5B | $860.0M |
| Tax Assets | $0 | $0 | $0 | $0 | $0 | $1.5B | $1.4B | $1.4B |
| Other Non-current Assets | $17.3B +12.4% | $15.4B +157.5% | $6.0B +21.5% | $4.9B +23.8% | $4.0B | $1.4B | $1.0B | $679.4M |
| Total Non-current Assets | $60.7B +5.1% | $57.8B +14.3% | $50.5B +2.7% | $49.2B -3.4% | $51.0B | -$15.3B | $14.8B | $11.3B |
| Total Assets | $86.7B +6.5% | $81.4B +11.2% | $73.2B -1.6% | $74.4B -1.0% | $75.2B | $13.3B | $11.9B | $10.6B |
| Account Payables | $4.2B +1.1% | $4.2B -2.3% | $4.3B -6.8% | $4.6B +4.5% | $4.4B | $1.3B | -$1.5B | $1.4B |
| Short-term Debt | $3.3B +88.7% | $1.8B +32.4% | $1.3B -46.6% | $2.5B +148.3% | $999.0M | -$1.6B | -$1.6B | $326.6M |
| Tax Payables | $569.0M -4.2% | $594.0M +20.7% | $492.0M +43.4% | $343.0M +12.1% | $306.0M | $574.4M | -$1.5B | $1.4B |
| Deferred Revenue | $0 | $0 | $0 | $0 | $0 | -$1.6B | $374.2M | $542.2M |
| Other Current Liabilities | $5.5B -6.4% | $5.9B -3.6% | $6.1B -5.7% | $6.5B +12.7% | $5.8B | $1.1B | $1.5B | $493.2M |
| Total Current Liabilities | $16.5B +16.5% | $14.2B +2.3% | $13.8B -10.6% | $15.5B +18.2% | $13.1B | $6.0B | $10.1B | $14.3B |
| Long-term Debt | $10.8B -14.2% | $12.6B -7.2% | $13.6B -6.4% | $14.5B -16.0% | $17.3B | $1.3B | $438.6M | $1.3B |
| Deferred Tax Liabilities | $2.0B +42.6% | $1.4B +12.6% | $1.2B -33.8% | $1.8B -11.1% | $2.1B | $746.6M | $612.2M | $477.8M |
| Deferred Revenue (Non-current) | $0 | $0 | $0 | $0 | $0 | -$1.6B | $715.8M | $1.3B |
| Other Non-current Liabilities | $3.7B -16.4% | $4.5B -6.6% | $4.8B +0.9% | $4.7B -17.5% | $5.7B | $489.0M | $1.1B | -$1.5B |
| Total Non-current Liabilities | $17.4B -9.9% | $19.4B -5.8% | $20.5B -6.8% | $22.0B -15.4% | $26.1B | $3.9B | $7.5B | $14.1B |
| Total Liabilities | $33.9B +1.3% | $33.5B -2.5% | $34.4B -8.4% | $37.5B -4.2% | $39.2B | $14.7B | $3.7B | $9.6B |
| Common Stock | $25.5B +1.5% | $25.2B +1.1% | $24.9B +0.6% | $24.7B +1.0% | $24.5B | $651.4M | $517.0M | $382.6M |
| Retained Earnings | $49.8B +5.3% | $47.3B +25.8% | $37.6B +6.5% | $35.3B +11.8% | $31.5B | -$1.6B | $519.8M | $1.1B |
| Accumulated OCI | -$6.0B +24.1% | -$7.9B -0.9% | -$7.8B +2.6% | -$8.1B +3.9% | -$8.4B | $393.8M | $550.6M | $707.4M |
| Other Stockholders Equity | $0 | $0 | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Minority Interest | $641.0M +170.5% | $237.0M +5.8% | $224.0M +2.3% | $219.0M -1.4% | $222.0M | $1.4B | $337.8M | $931.4M |
| Total Equity | $52.8B +10.2% | $47.9B +23.4% | $38.8B +5.2% | $36.9B +2.4% | $36.0B | $9.1B | $7.7B | $3.3B |
| Total Debt | $15.1B -1.4% | $15.3B -3.8% | $15.9B -11.6% | $17.9B -6.8% | $19.3B | $724.2M | $410.6M | $399.4M |
| Net Debt | $6.5B -14.5% | $7.7B -14.7% | $9.0B +11.3% | $8.1B -14.7% | $9.5B | $389.6M | $501.6M | $311.2M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
UnitedHealth Group Incorporated
NYSE:UNH
$365.66B
Merck & Co., Inc.
NYSE:MRK
$281.68B
Novartis AG
NYSE:NVS
$280.83B
Novo Nordisk A/S
NYSE:NVO
$191.04B
Thermo Fisher Scientific Inc.
NYSE:TMO
$172.94B
Gilead Sciences, Inc.
NASDAQ:GILD
$152.42B
Intuitive Surgical, Inc.
NASDAQ:ISRG
$143.65B
Stryker Corporation
NYSE:SYK
$119.04B
Medtronic plc
NYSE:MDT
$101.32B
Boston Scientific Corporation
NYSE:BSX
$67.43B
SEC Filings
Recent regulatory filings
No filings found.
How much cash does ABT have?
Abbott Laboratories (ABT) reported $8.52B in cash and equivalents in fiscal 2025.
How much debt does ABT carry?
Abbott Laboratories (ABT) reported $15.07B of total debt, with net debt of $6.54B.
Explore More
Continue the stock analysis
Jump to another research area for this company.